Atorvastatin

證據等級: L5

預測適應症: 6 個

Atorvastatin: From Hypercholesterolaemia to Familial Hypercholesterolaemia

One-Sentence Summary

Atorvastatin is a widely used HMG-CoA reductase inhibitor (statin), primarily indicated for the management of hypercholesterolaemia and prevention of cardiovascular events. The TxGNN model predicts it may be effective for Familial Hypercholesterolaemia (FH), with 35 clinical trials and 19 publications currently supporting this direction. This prediction carries a high-confidence score of 99.42% and aligns with established clinical practice globally, effectively validating the model’s predictive performance for this drug–disease pairing.

Quick Overview

Item	Content
Original Indication	Hypercholesterolaemia and cardiovascular risk reduction (UK MHRA licensing data not retrieved in this evidence pack — see note in UK Market Information section)
Predicted New Indication	Familial Hypercholesterolaemia
TxGNN Prediction Score	99.42%
Evidence Level	L1
UK Market Status	Not retrieved (data gap; Atorvastatin is known to be commercially available in the UK)
Number of Marketing Authorisations	0 (data collection gap — does not reflect actual MHRA authorisation status)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data was not returned in this evidence pack. However, based on well-established pharmacological knowledge, Atorvastatin competitively inhibits HMG-CoA reductase — the rate-limiting enzyme in hepatic cholesterol biosynthesis. By reducing intracellular cholesterol in hepatocytes, the drug triggers compensatory upregulation of LDL receptors (LDLR) on the hepatocyte surface, substantially increasing the clearance of circulating LDL-C. Atorvastatin also reduces the hepatic production of apolipoprotein B-containing lipoproteins and has a prolonged plasma half-life (~20–30 hours) relative to earlier statins, enabling sustained 24-hour HMG-CoA reductase inhibition.

Familial Hypercholesterolaemia is a hereditary condition characterised by loss-of-function mutations in the LDLR, APOB, or PCSK9 genes, resulting in severely impaired LDL-C clearance and markedly elevated LDL-C levels from birth. The compensatory upregulation of LDL receptors induced by atorvastatin directly addresses — albeit partially — the core pathophysiological deficit. In heterozygous FH (heFH), where at least one functional LDLR allele is preserved, atorvastatin typically achieves 40–50% LDL-C reductions. In homozygous FH (HoFH), residual receptor activity is near-absent and combination therapy (ezetimibe, PCSK9 inhibitors, or LDL apheresis) is generally required alongside a statin.

The biological plausibility is strongly reinforced by the clinical evidence base: multiple completed Phase 3 trials, long-term paediatric studies, and major clinical guidelines — including NICE CG71 (Familial Hypercholesterolaemia) and the AACE/ACE Dyslipidaemia Guidelines — consistently position high-intensity statins, including atorvastatin, as the cornerstone of FH management. The TxGNN prediction score of 99.42% reflects this near-universal mechanistic and clinical concordance.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00827606	Phase 3	Completed	272	Three-year open-label study of atorvastatin in children and adolescents (from age 6) with heFH; characterised sustained LDL-C reduction, growth, BMI, and Tanner Stage development
NCT00136981	Phase 3	Completed	800	Large double-blind RCT comparing torcetrapib/atorvastatin vs maximally tolerated atorvastatin alone in heFH; carotid intima-media thickness assessed over 24 months; torcetrapib arm terminated due to safety findings
NCT00134485	Phase 3	Completed	400	Six-month double-blind RCT of torcetrapib/atorvastatin vs atorvastatin monotherapy in heFH; provides direct comparator data for atorvastatin LDL-C lowering efficacy in FH
NCT00134511	Phase 3	Completed	30	Forced-titration open-label study of torcetrapib/atorvastatin in HoFH; evaluated efficacy and safety in the most severe FH phenotype
NCT03885921	Phase 3	Completed	44	Long-term (24-month) open-label extension assessing safety and tolerability of ezetimibe co-administered with atorvastatin or simvastatin in HoFH
NCT03867318	Phase 3	Completed	621	Double-blind efficacy and safety study of ezetimibe 10 mg added to atorvastatin 10 mg in heFH or CHD/multiple cardiovascular risk factors with inadequately controlled primary hypercholesterolaemia
NCT03882996	Phase 3	Completed	432	Twelve-month open-label long-term safety of ezetimibe co-administered with atorvastatin 10–80 mg daily in heFH or CHD/multiple cardiovascular risk factors
NCT00739999	Phase 1	Completed	39	Eight-week study evaluating the pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin specifically in children and adolescents with heFH
NCT02460159	Phase 3	Completed	135	Long-term safety of ezetimibe/atorvastatin fixed-dose combination (10/10 mg and 10/20 mg) in Japanese patients with hypercholesterolaemia not controlled on statin monotherapy
NCT01730040	Phase 3	Completed	355	Double-blind study comparing alirocumab vs ezetimibe added to atorvastatin, vs atorvastatin dose increase, vs switch to rosuvastatin, in high cardiovascular-risk patients including heFH not controlled on atorvastatin

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28437620	2017	Clinical Practice Guideline	Endocrine Practice	AACE/ACE dyslipidaemia guidelines; positions high-intensity statins, including atorvastatin, as first-line therapy in FH with defined LDL-C targets
27417002	2016	Cohort/Outcomes Study	JACC	Statin therapy in heFH substantially reduces coronary artery disease event rates and all-cause mortality; quantifies absolute risk reduction in a defined FH population
39751968	2025	Narrative Review	Curr Atheroscler Rep	Review of emerging pharmacological therapies for HoFH; contextualises the role of statins (including atorvastatin) as a foundation alongside PCSK9 inhibitors and novel agents
27678432	2016	Clinical Study	J Clin Lipidol	Three-year real-world study of atorvastatin in children/adolescents aged 6–17 years with heFH; demonstrates sustained LDL-C lowering and no adverse effects on growth or development
11383320	2001	Comparative Trial	Nutr Metab Cardiovasc Dis	Head-to-head comparison of atorvastatin vs simvastatin in heFH; atorvastatin achieved NCEP LDL-C goals in a higher proportion of patients with additional favourable effects on fibrinogen
22957727	2013	Interventional Study	Echocardiography	Atorvastatin therapy improves myocardial and peripheral blood flow reserve in FH subjects without overt coronary atherosclerosis, demonstrating early vascular pleiotropic benefits
9793596	1998	Clinical Review	Ann Pharmacother	Comprehensive review of atorvastatin pharmacology, efficacy, and safety in primary hypercholesterolaemia and mixed dyslipidaemias; foundational reference for dosing principles
26988948	2016	Review	JACC	Review of monitoring and care strategies for FH patients; emphasises intensive statin therapy as an essential component of long-term cardiovascular risk management
35361995	2022	Genetic Epidemiology Study	Pharmacogenomics J	Next-generation sequencing strategy combining FH gene panels with pharmacogenomic regions relevant to statin prescription; supports genotype-guided atorvastatin selection and dose optimisation
10582478	1999	Drug Review	Rev Med Bruxelles	Overview of atorvastatin mechanism (HMG-CoA reductase inhibition), prolonged half-life of active metabolites, and biological efficacy in cholesterol reduction, including LDL-C, TG, and Apo B reductions

UK Market Information

⚠️ Data Collection Gap: This evidence pack recorded 0 marketing authorisations and a market status of “not marketed” for Atorvastatin in the UK. This is inconsistent with the well-established commercial presence of Atorvastatin in the UK under the brand name Lipitor (Pfizer) and numerous MHRA-approved generic formulations. This appears to be a failure in the data collection pipeline for this run and should be remediated by querying the MHRA Product Licence database directly.

For current, authoritative UK prescribing information, refer to:

BNF Chapter 2.12 — Lipid-regulating drugs (Atorvastatin monograph)
MHRA Product Licence search for Atorvastatin calcium tablets
NICE CG71 — Identification and management of Familial Hypercholesterolaemia
NICE TA385 — Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (contextualises statin background therapy)
SmPC for Lipitor and relevant generic products

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for atorvastatin in familial hypercholesterolaemia is exceptionally robust (Evidence Level L1), comprising multiple completed Phase 3 randomised trials in both heterozygous and homozygous FH — including paediatric populations — as well as endorsement in major international clinical guidelines including NICE CG71. The TxGNN prediction (99.42%) effectively validates the model’s performance by confirming an established clinical indication rather than proposing a novel one. The principal guardrails relate to ensuring appropriate patient stratification (heFH vs HoFH), managing combination therapy decisions, and resolving the UK licensing data gap.

To proceed, the following is needed:

Resolve the UK licensing data gap: Re-run the MHRA product licence data collection pipeline to accurately capture all current marketing authorisations for atorvastatin in the UK
Retrieve formal MOA data: Query the DrugBank API for DB01076 to populate the mechanism of action field (flagged as High severity data gap in this evidence pack)
Obtain full UK safety profile: Retrieve MHRA SmPC warnings, contraindications, and drug interactions — particularly for CYP3A4 interactions (e.g., ciclosporin, clarithromycin, strong CYP3A4 inhibitors) relevant to FH patients on complex regimens
HoFH-specific pathway: For homozygous FH patients, document eligibility criteria for LDL apheresis (NICE CG71) and PCSK9 inhibitor access (NICE TA393/TA394) as atorvastatin monotherapy is insufficient in this subgroup
Paediatric dosing review: Confirm MHRA-approved age indications and dose ranges for children with FH, with reference to the atorvastatin SmPC and NICE CG71 paediatric recommendations
Pharmacogenomic consideration: Review CYP3A4 and SLCO1B1 genotyping opportunities for FH patients at high risk of statin-associated myopathy, as highlighted in the pharmacogenomics literature
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.